Roflumilast Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor-α and Chemokine Production by Human Lung Parenchyma

BACKGROUND: Roflumilast is the first phosphodiesterase-4 (PDE4) inhibitor to have been approved for the treatment of COPD. The anti-inflammatory profile of PDE4 inhibitors has not yet been explored in human lung tissues. We investigated the effects of roflumilast and its active metabolite roflumilas...

Descripción completa

Detalles Bibliográficos
Autores principales: Buenestado, Amparo, Chaumais, Marie-Camille, Grassin-Delyle, Stanislas, Risse, Paul-André, Naline, Emmanuel, Longchampt, Elisabeth, Tenor, Hermann, Devillier, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774805/
https://www.ncbi.nlm.nih.gov/pubmed/24066150
http://dx.doi.org/10.1371/journal.pone.0074640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774805/
https://www.ncbi.nlm.nih.gov/pubmed/24066150
http://dx.doi.org/10.1371/journal.pone.0074640

Ejemplares similares